Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations. (September 2020)

• Record Type: Journal Article
• Authors: Gauzy-Lazo, Laurence; Sassoon, Ingrid; Brun, Marie-Priscille
• Is Part Of: SLAS discovery. Volume 25:Number 8(2020)
• Page Start: 843
• Page End: 868
• Publication Date: 2020-09
• Subjects: antibody–drug conjugate -- cytotoxic payload -- site-specific conjugation -- alternative formats; Drugs -- Analysis -- Periodicals; Drugs -- Testing -- Periodicals; Biomolecules -- Analysis -- Periodicals; Biomolecules -- Analysis; Drugs -- Analysis; Drugs -- Testing; Drug Evaluation, Preclinical; Molecular Biology -- methods; Periodicals; Periodicals; 615.1
• DOI: 10.1177/2472555220912955
• Languages: English
• ISSNs: 2472-5552

Abstract

The targeted delivery of potent cytotoxic molecules into cancer cells is considered a promising anticancer strategy. The design of clinically effective antibody–drug conjugates (ADCs), in which biologically active drugs are coupled through chemical linkers to monoclonal antibodies, has presented challenges for pharmaceutical researchers. After 30 years of intensive research and development activities, only seven ADCs have been approved for clinical use; two have received fast-track designation and two breakthrough therapy designation from the Food and Drug Administration. There is continued interest in the field, as documented by the growing number of candidates in clinical development. This review aims to summarize the most recent innovations that have been applied to the design of ADCs undergoing early- and late-stage clinical trials. Discovery and rational optimization of new payloads, chemical linkers, and antibody formats have improved the therapeutic index of next-generation ADCs, ultimately resulting in improved clinical benefit for the patients.